CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)

Cordis US Corp.2,070 enrolled

Overview

The purpose of this PMS registry, named e-CYPHER Stent Registry, is to collect post marketing surveillance data on the CYPHERTM Sirolimus-eluting Coronary Stent following marketing approval, when used in normal clinical practice within the labeled indications.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

2,070

Conditions

Coronary Artery Disease

Interventions

CYPHERTM Sirolimus-Eluting Coronary StentDEVICE

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Cypher stent Exclusion Criteria: * N/A

Outcomes

Primary Outcomes

MACE at 30 days, 6 months and 1 year.

Secondary Outcomes

There is no pre-specified secondary outcome.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.